Aerocrine appoints Vice President Global Sales

Aerocrine appoints Vice President Global Sales

SOLNA - 17 September, 2007 - Aerocrine appoints new senior sales position
whereby Anna Malm Bernsten joins Aerocrine's management team from mid September
with the responsibility for global sales.

Anna Malm Bernsten has more than 20 years management experience within
international marketing and sales, with broad experience from diagnostics,
medical technology and pharmaceuticals. Anna currently serves as board member of
Artimplant, Medivir and Fagerhult.

Anna was previously CEO of Carmeda and managed a comprehensive restructuring of
the company as well as a successful company sale to the Gore group in the United
States. In the beginning of the 2000s, Anna was a member of the group management
team at ASSA ABLOY AB in charge of building a common corporate identity for more
than 100 merged companies. One of the tools was the Volvo Ocean Race. In 2002,
Anna was appointed Project Leader of the Year by Svenska Projektakademien. Most
recently, she ran her own management and business development company. 

“We are very happy to have recruited Anna as head of global sales. Aerocrine is
entering into a commercialization phase when geographic expansion and further
development of our sales channels are important challenges,” says Paul de
Potocki, CEO of Aerocrine. “Anna's solid experience and documented operational
abilities will help us achieve our ambitions.”

For more information, contact:

Paul de Potocki, CEO, phone: +46 8 629 0780
Anna Malm Bernsten, VP Global Sales, phone: +46 70 559 8541

About Aerocrine
Aerocrine AB (publ.) is a clinically based medical technology corporation
dedicated to improved asthma management and care. Aerocrine was listed on the
Stockholm Stock Exchange on 15 June, 2007. The company is marketing NIOX ® Flex
on a worldwide basis and is also marketing NIOX MINO®, representing a new
generation of hand-held devices, in Europe. Both products are tailored for
rapid, non-invasive control of the inflammatory status in the airways and may
play a critical role for a more efficient diagnosis, treatment and monitoring of
asthma patients. Aerocrine is located in Sweden with wholly owned subsidiaries
in the US, UK and Germany.